Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM

被引：5
|
作者：
Ohwaki, Kenji
Furihata, Kenichi
Mimura, Hanaka
Oura, Tomonori
Imaoka, Takeshi
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-1024-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1024-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)
    Ludvik, Bernhard
    Giorgino, Francesco
    Jodar, Esteban
    Frias, Juan Pablo
    Lando, Laura Fernandez
    Brown, Katelyn
    Bray, Ross
    Rodriguez, Angel
    DIABETES, 2021, 70
  • [42] The dual GIP/GLP-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
    Wilson, J. M.
    Nikooienejad, A.
    Bowsman, L. M.
    Schroeder, J. M.
    Hamlin, D. M.
    Robins, D. A.
    Riesmeyer, J. S.
    Haupt, A.
    Duffin, K. L.
    Ruotolo, G.
    DIABETOLOGIA, 2019, 62 : S558 - S559
  • [43] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan
    Duffin, Kevin
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02): : 388 - 396
  • [44] A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
    Al-Zamel, Noura
    Al-Sabah, Suleiman
    Luqmani, Yunus
    Adi, Lobna
    Chacko, Siby
    Schneider, Tom Dario
    Krasel, Cornelius
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (14)
  • [45] Efficacy and safety of tirzepatide, a dual GIP/GLP-1 receptor agonist, compared to insulin degludec in patients with type 2 diabetes (SURPASS-3)
    Ludvik, B.
    Giorgino, F.
    Jodar, E.
    Frias, J. P.
    Lando, L. Fernandez
    Brown, K.
    Bray, R.
    Rodriguez, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 245 - 245
  • [46] Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan M.
    Duffin, Kevin L.
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    DIABETES, 2019, 68
  • [47] Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
    Nowak, Mariusz
    Nowak, Wojciech
    Grzeszczak, Wladyslaw
    ENDOKRYNOLOGIA POLSKA, 2022, 73 (04) : 745 - 755
  • [48] Efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes
    Nauck, M. A.
    Frias, J. P.
    Van, J.
    Benson, C. T.
    Bray, R.
    Milicevic, Z.
    Haupt, A.
    Robins, D. A.
    DIABETOLOGIA, 2019, 62 : S59 - S59
  • [49] Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease
    Aldrich, Sarah
    Ashjian, Emily
    NURSE PRACTITIONER, 2019, 44 (03): : 20 - 28
  • [50] Dose-Response Improvements in Glycemic Control and Body Weight Reductions with HM11260C, a Once-Weekly GLP-1 Receptor Agonist with Liraglutide as Reference, in Type 2 Diabetes (T2DM)
    Rosenstock, Julio
    Kang, Jahoon
    Choi, Soomin
    Kim, Soojin
    Han, Oakpil
    Kil, Siyoen
    Gee, Kyuhoon
    Choi, In Young
    Kwon, Se Chang
    Trautmann, Michael
    Hompesch, Marcus
    DIABETES, 2015, 64 : A73 - A73
12345